Marshall Wace LLP Increases Stake in Evolent Health, Inc. (NYSE:EVH)

Marshall Wace LLP raised its position in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 45.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 94,320 shares of the technology company's stock after purchasing an additional 29,328 shares during the period. Marshall Wace LLP owned about 0.08% of Evolent Health worth $1,061,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Summit Creek Advisors LLC raised its holdings in shares of Evolent Health by 0.8% in the fourth quarter. Summit Creek Advisors LLC now owns 202,114 shares of the technology company's stock valued at $2,274,000 after acquiring an additional 1,636 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Evolent Health in the 4th quarter worth approximately $26,000. Parkside Financial Bank & Trust lifted its position in shares of Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after purchasing an additional 2,358 shares during the period. Johnson Investment Counsel Inc. boosted its stake in shares of Evolent Health by 28.0% during the fourth quarter. Johnson Investment Counsel Inc. now owns 11,607 shares of the technology company's stock valued at $131,000 after purchasing an additional 2,542 shares in the last quarter. Finally, R Squared Ltd purchased a new position in Evolent Health during the fourth quarter valued at approximately $31,000.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Oppenheimer lowered their target price on Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a report on Friday, January 24th. Needham & Company LLC restated a "buy" rating and set a $15.00 price objective on shares of Evolent Health in a research note on Friday, February 21st. Stephens cut their target price on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Tuesday, January 21st. Royal Bank of Canada reduced their target price on shares of Evolent Health from $20.00 to $17.00 and set an "outperform" rating for the company in a report on Tuesday, January 14th. Finally, Citigroup lowered their price target on shares of Evolent Health from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Evolent Health currently has an average rating of "Buy" and a consensus target price of $17.71.

Insider Buying and Selling

In other Evolent Health news, CEO Seth Blackley purchased 55,225 shares of Evolent Health stock in a transaction on Thursday, March 6th. The stock was bought at an average cost of $9.01 per share, with a total value of $497,577.25. Following the transaction, the chief executive officer now owns 762,217 shares of the company's stock, valued at $6,867,575.17. This represents a 7.81 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Daniel Joseph Mccarthy acquired 11,040 shares of the company's stock in a transaction dated Thursday, March 6th. The stock was acquired at an average cost of $9.01 per share, for a total transaction of $99,470.40. Following the completion of the acquisition, the president now directly owns 389,004 shares in the company, valued at approximately $3,504,926.04. The trade was a 2.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 74,000 shares of company stock valued at $666,315 over the last quarter. 1.60% of the stock is currently owned by company insiders.

Evolent Health Stock Performance

Evolent Health stock traded down $0.27 during mid-day trading on Monday, reaching $10.42. 164,820 shares of the company traded hands, compared to its average volume of 2,366,050. The firm's fifty day moving average is $9.48 and its two-hundred day moving average is $11.92. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -12.71 and a beta of 1.20. Evolent Health, Inc. has a fifty-two week low of $8.35 and a fifty-two week high of $33.63. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The firm had revenue of $646.54 million during the quarter, compared to analyst estimates of $650.92 million. On average, equities research analysts expect that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.